Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) reported disappointing Phase 2 study results weighing the stock price down 48 cents to close at $3.05.
Rigel Pharmaceuticals' study results disappoint
April 03, 2018 at 18:49 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.